These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10618912)

  • 1. [Inactivation of BVDV (experimental model for hepatitis C) using low pH and heat treatment in intravenous human immunoglobulins].
    Ruibal Brunet IJ; Noa Romero E; Rivero Mas AT; Martín García RZ
    Sangre (Barc); 1999 Oct; 44(5):352-6. PubMed ID: 10618912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.
    Louie RE; Galloway CJ; Dumas ML; Wong MF; Mitra G
    Biologicals; 1994 Mar; 22(1):13-9. PubMed ID: 8068309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
    Borovec S; Broumis C; Adcock W; Fang R; Uren E
    Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
    Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
    J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
    Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
    Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
    Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
    Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
    Welch J; Bienek C; Gomperts E; Simmonds P
    Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
    Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bovine viral diarrhea virus is inactivated when whole milk from persistently infected cows is heated to prepare semen extender.
    Marley MS; Tabor JM; Givens MD; Kaproth M; Riddell KP; Galik PK; Zhang Y; Eason AB
    Vet Microbiol; 2009 Mar; 134(3-4):249-53. PubMed ID: 18950967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary studies on inactivation of serum HCV].
    Liu FH; Tian GS; Fu XX
    Zhonghua Yu Fang Yi Xue Za Zhi; 1994 Jan; 28(1):3-5. PubMed ID: 8082457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrhenius relationships from the molecule and cell to the clinic.
    Dewey WC
    Int J Hyperthermia; 2009 Feb; 25(1):3-20. PubMed ID: 19219695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase.
    Paeshuyse J; Letellier C; Froeyen M; Dutartre H; Vrancken R; Canard B; De Clercq E; Gueiffier A; Teulade JC; Herdewijn P; Puerstinger G; Koenen F; Kerkhofs P; Baraldi PG; Neyts J
    Antiviral Res; 2009 Jun; 82(3):141-7. PubMed ID: 19428605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on continuous (254 nm) and pulsed UV (266 and 355 nm) lights on BVD virus inactivation and its effects on biological properties of fetal bovine serum.
    Azar Daryany MK; Hosseini SM; Raie M; Fakharie J; Zareh A
    J Photochem Photobiol B; 2009 Feb; 94(2):120-4. PubMed ID: 19095459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
    Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
    Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.